<DOC>
	<DOCNO>NCT00332774</DOCNO>
	<brief_summary>The purpose study determine safety Nevanac 0.1 % compare Acular LS 0.4 % Vehicle patient treat cataract surgery approximately 90 day follow surgery .</brief_summary>
	<brief_title>Nevanac 3-Month Safety Study With QID Dosing</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients race sex age 10 year old undergoing cataract extraction plan implantation posterior chamber intraocular lens . Other protocoldefined inclusion criterion may apply . Under 10 Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>